Michael E. Borok, MD
Specialist
17075 Devonshire St, Suite 203
Northridge, CA 91325
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Irvine, California College of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 57
Licensed in California since 1983, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: University of California, Irvine, California College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
CA license G50681 (first issued 1983; current) -
Dermatopathology Physician
CA license G50681 (first issued 1983; current) -
Procedural Dermatology Physician
CA license G50681 (first issued 1983; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 57
- Services billed
- 175
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 111 | 60 |
| Established patient office or other outpatient visit, 30-39 minutes | 39 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
| Pathology examination of tissue using a microscope, intermediate complexity | 16 | 14 |
| Destruction of skin growth, 1-14 growths | 16 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluocinonide Other prescribers in Northridge, CA | 68 |
| Ketoconazole Other prescribers in Northridge, CA | 53 |
| Hydrocortisone Other prescribers in Northridge, CA | 27 |
| Triamcinolone Acetonide Other prescribers in Northridge, CA | 26 |
| Metronidazole Other prescribers in Northridge, CA | 20 |
| Clotrimazole-Betamethasone (clotrimazole/betamethasone dip) Other prescribers in Northridge, CA | 20 |
| Ciclopirox Other prescribers in Northridge, CA | 19 |
| Fluorouracil Other prescribers in Northridge, CA | 18 |
| Dupixent Syringe (dupilumab) Other prescribers in Northridge, CA | 17 |
| Calcipotriene-Betamethasone (calcipotriene/betamethasone) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 15 payments worth $255 in total to this clinician.
| AbbVie Inc. | $75.95 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $48.19 |
| Amgen Inc. | $32.94 |
| Janssen Biotech, Inc. | $29.51 |
| Arcutis Biotherapeutics, Inc. | $19.33 |
| Verrica Pharmaceuticals Inc. | $19.19 |
| Incyte Corporation | $14.91 |
| Almirall LLC | $14.66 |
| Food and Beverage | $255 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $7,598 in research payments for these studies, mostly to the institutions running them.
- A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
UCB SA · Completed · NCT05277571
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.